{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:26:32Z","timestamp":1772756792170,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":127,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006617.pub2","type":"reference-entry","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T01:11:33Z","timestamp":1202260293000},"source":"Crossref","is-referenced-by-count":13,"title":["Aripiprazole versus typicals for schizophrenia"],"prefix":"10.1002","author":[{"given":"J","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HGG","family":"El-Sayeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"key":"10.1002\/14651858.CD006617.pub2-BIB3|cit1","doi-asserted-by":"crossref","first-page":"103s","DOI":"10.1016\/S0924-9338(02)80465-5","article-title":"Controlled study of aripiprazole and haloperidol in schizophrenia","volume":"Suppl 1","author":"Anutosh","year":"2002","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB14|cit2","unstructured":"Aquino P CE Adams T Crow I Wood Personal communication Personal Communication 2006"},{"key":"10.1002\/14651858.CD006617.pub2-BIB7|cit3","first-page":"221","article-title":"A double-blind, placebo-controlled trial of aripiprazole and haloperidol","volume":"1-2","author":"Carson","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB5|cit4","series-title":"39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico","article-title":"A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder","author":"Carson","year":"2000"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006617.pub2-BIB1|cit5","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S0924-977X(00)80358-2","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"10","author":"Carson","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB12|cit6","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub2-BIB10|cit7","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub2-BIB11|cit8","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 176 232"},{"key":"10.1002\/14651858.CD006617.pub2-BIB13|cit9","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub2-BIB6|cit10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0920-9964(00)90383-9","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"1","author":"Kane","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB4|cit11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"9","author":"Kane","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB8|cit12","series-title":"153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","author":"Kane","year":"2000"},{"key":"10.1002\/14651858.CD006617.pub2-BIB2|cit13","series-title":"155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","author":"Kane","year":"2002"},{"key":"10.1002\/14651858.CD006617.pub2-BIB9|cit14","first-page":"S124","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"Suppl 1","author":"Kane","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB15|cit15","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub2-BIB17|cit16","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 51 110"},{"key":"10.1002\/14651858.CD006617.pub2-BIB16|cit17","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub2-BIB18|cit18","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub2-BIB19|cit19","first-page":"S157","article-title":"Aripiprazole, a novel antipsychotic: overview of a phase II study result","volume":"Suppl 1","author":"Daniel","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB22|cit20","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub2-BIB21|cit21","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub2-BIB24|cit22","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub2-BIB23|cit23","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub2-BIB20|cit24","first-page":"295","article-title":"Safety and efficacy profile of aripiprazole, a novel antipsychotic","volume":"1-3","author":"Saha","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB25|cit25","series-title":"157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, Usa","article-title":"Intramuscular aripiprazole in acutely agitated psychotic patients","author":"Daniel","year":"2004"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub2-BIB27|cit26","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0924-977X(04)80286-4","article-title":"Intramuscular aripiprazole treatment for acute agitation in patients with psychosis","volume":"14","author":"Gismondi","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB26|cit27","series-title":"Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy","article-title":"Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis","author":"Kungel","year":"2004"},{"key":"10.1002\/14651858.CD006617.pub2-BIB28|cit28","unstructured":"Modell S Daniel D Stock E Wilber R Marcus R Carson W Manos G Iwamoto T Intramuscular aripiprazole treatment for acute agitation in patients with psychosis XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24, Paris, France 2004"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomised double-blind,placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB30|cit30","series-title":"43rd Annual Meeting of the American College of Neuropsychopharmacology ; 2004 Dec 12-16, San Juan, Puerto Rico","article-title":"Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis","author":"Yocca","year":"2004"},{"key":"10.1002\/14651858.CD006617.pub2-BIB38|cit31","unstructured":"Gismondi R Meltzer H Kujawa M Carson W Stringfellow J Iwamoto T Marcus R Stock E Aipiprazole versus perphenazine in treatment-resistant schizophrenia XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24, Paris, France 2004"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB35|cit32","first-page":"155","article-title":"Aripiprazole in Treatment-Resistant Schizophrenia: a 6-Week Double- Blind Comparison Study Versus Perphenazine","volume":"67","author":"Kane","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB31|cit33","series-title":"156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA","article-title":"Aripiprazole vs. perphenazine in treatment-resistant schizophrenia","author":"Kane","year":"2003"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub2-BIB37|cit34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia : results of a multicenter, randomised, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB33|cit35","series-title":"16th European College of Neuropsychopharmacology Congress ; 2003 Sep 20-24; Prague, Czech Republic","article-title":"Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia","author":"McQuade","year":"2003"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub2-BIB32|cit36","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S0924-977X(03)92058-X","article-title":"Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia","volume":"13","author":"McQuade","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB34|cit37","series-title":"157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, Usa","article-title":"Aripiprazole and perphenazine in severe treatment-resistant schizophrenia","author":"Meltzer","year":"2004"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub2-BIB39|cit38","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0924-977X(04)80296-7","article-title":"Efficacy of aripiprazole and perphenazine in svere schiziphrenia resistant to treatment with atypical antipsychotics","volume":"14","author":"Modell","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB36|cit39","first-page":"502","article-title":"Aripiprazole versus Perphenazine in Treatment - Resistant Schizophrenia","volume":"31","author":"Sanchez","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB51|cit40","first-page":"155","article-title":"Effects of Long-Term Aripiprazole Therapy on the Negative Symptoms of Schizophrenia","volume":"67","author":"Archibald","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB48|cit41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0920-9964(03)80424-3","article-title":"Reduction in negative symptoms of schizophrenia during long-term therapy with aripiprazole","volume":"60","author":"Archibald","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB56|cit42","series-title":"158th Annual Meeting of the American Psychiatric Association ; 2005 May 21-26; Atlanta, Georgia, USA","article-title":"Is sedation needed for effective reduction of acute schizophrenia symptoms ?","author":"Crandall","year":"2005"},{"key":"10.1002\/14651858.CD006617.pub2-BIB55|cit43","unstructured":"Dubitsky GM Harris R Laughren T Hardeman s Abilify (aripiprazole) tablets ; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub2-BIB46|cit44","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub2-BIB54|cit45","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub2-BIB53|cit46","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub2-BIB57|cit47","series-title":"159th Annual Meeting of the American Psychiatric Association ; 2006 May 20-25, Toronto, Canada","article-title":"Long-term symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol","author":"Kane","year":"2006"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub2-BIB50|cit48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(03)92064-5","article-title":"Long-term effects of aripirazole on the negative symptoms of schizophrenia","volume":"13","author":"Kostic","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB58|cit50","series-title":"Schizophrenia Bulletin","first-page":"492","article-title":"Maintenance of responce in chronic schizophrenia : effects of aripiprazole and haloperidol on affective symptoms","author":"Kostic","year":"2005"},{"key":"10.1002\/14651858.CD006617.pub2-BIB40|cit51","first-page":"S186","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"suppl 1","author":"Kujawa","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB45|cit52","series-title":"155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA","article-title":"Aripiprazole for long-term maintenance treatment in schizophrenia","author":"Kujawa","year":"2002"},{"key":"10.1002\/14651858.CD006617.pub2-BIB42|cit53","series-title":"156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA","article-title":"Long-term effects of aripiprazole on the negative symptoms of schizophrenia","author":"Manos","year":"2003"},{"key":"10.1002\/14651858.CD006617.pub2-BIB59|cit54","unstructured":"Marder SR Archibald DG Manos G Stock EG Jody DN Tourkodimitris S Marcus RN Iwamoto T Yamomoto Y Carson WH Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24 , Paris, France 2004"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD006617.pub2-BIB43|cit55","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S0924-977X(02)80405-9","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"12","author":"McQuade","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB47|cit56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0920-9964(03)80498-X","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"60","author":"McQuade","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub2-BIB61|cit57","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0924-977X(04)80287-6","article-title":"Long-term effects of aripiprazole on affective symptoms of schizophrenia","volume":"14","author":"Octavio","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB60|cit58","unstructured":"Octavio I Stock EG Archibald DG Tourkodimitris S Kujawa MJ Marcus R Carson WH Iwamoto T Long-term effects of aripiprazole on affective symptoms of schizophrenia XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24, Paris, France 2004"},{"key":"10.1002\/14651858.CD006617.pub2-BIB44|cit59","series-title":"XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan","article-title":"Long-term aripiprazole therapy in schizophrenia","author":"Saha","year":"2002"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB52|cit60","first-page":"158","article-title":"Long-Term Effects of Aripiprazole and Haloperidol on Affective Symptoms of Schizophrenia","volume":"67","author":"Stock","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB41|cit61","series-title":"156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA","article-title":"Long-term effects of arpiprazole on affective symptoms of schizophrenia","author":"Stock","year":"2003"},{"issue":"Nov","key":"10.1002\/14651858.CD006617.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006617.pub2-BIB68|cit63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder ; a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB66|cit64","series-title":"159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada","article-title":"Benefits of a second dose of intramuscular (im) aripiprazole to control agitation in patients with schizophrenia or bipolar 1 disorder","author":"Citrome","year":"2006"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub2-BIB67|cit65","first-page":"S509","article-title":"Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients","volume":"15","author":"Dillenschneider","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB69|cit66","unstructured":"McQuade R Auby P Oren D Marcus R Kostic D Iwamoto T Manos G Intramuscular aripiprazole in acute schizophrenia : a double-blind, placebo-controlled comparison with IM haloperidol 13th Biennial winter workshop on Schizophrenia Research; 2006 February 4-10, Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD006617.pub2-BIB65|cit67","unstructured":"Oren D Marcus R Kostic D McQuade R Iwamoto T Archibald D Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, GA, USA 2005"},{"key":"10.1002\/14651858.CD006617.pub2-BIB63|cit68","first-page":"499","article-title":"Efficacy and Safety of Intramuscular Aripiprazole, Haloperidol or Placebo in Acutely Agitated Patients with Schizophrenia or Schizoaffective Disorder","volume":"31","author":"Oren","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub2-BIB64|cit69","unstructured":"Yocca F Marcus R Oren D Manos G Carson W Iwamoto T Stock E Intramuscular aripiprazole in acute schizophrenia: A pivotal phase-three study 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA, USA 2005"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub2-BIB70|cit70","first-page":"250","article-title":"A comparative study between aripiprazole and chlorpromazine in the treatment of schizophrenia","volume":"18","author":"Wang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1592\/phco.24.2.212.33145","article-title":"Aripiprazole, a novel atypical antipsychotic drug","volume":"24","author":"Argo","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD006617.pub2-BIB72|cit72","series-title":"XIIth World Congress of Psychiatry; Aug 24-29; Yokohama, Japan","author":"Carson","year":"2002"},{"key":"10.1002\/14651858.CD006617.pub2-BIB73|cit73","unstructured":"Carson W Marcus R Jody D Liston H Pans M Riera L Iwamoto T The effectiveness of switch to aripiprazole stratified by prior antipsychotic American Psychiatric Association Annual Meeting; 2004 May 1-6, New York, NY, USA 2004"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006617.pub2-BIB74|cit74","first-page":"S187","article-title":"Switching to aripiprazole monotherapy","volume":"5","author":"Casey","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub2-BIB76|cit75","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents : a multicenter randomised study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB75|cit76","series-title":"155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennysylvania, USA","article-title":"Switching to aripiprazole monotherapy","author":"Casey","year":"2002"},{"key":"10.1002\/14651858.CD006617.pub2-BIB80|cit77","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub2-BIB79|cit78","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub2-BIB78|cit79","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub2-BIB77|cit80","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub2-BIB82|cit81","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0920-9964(03)80483-8","article-title":"Switching to aripiprazole monotherapy","volume":"60","author":"Kujawa","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006617.pub2-BIB81|cit82","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/S0924-977X(02)80418-7","article-title":"Switching to aripiprazole monotherapy","volume":"12","author":"Medori","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006617.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia ?","volume":"16","author":"Kelemen","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006617.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/S0924-977X(06)70527-2","article-title":"The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder : results for 16-week clinical study","volume":"16","author":"Kim","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB85|cit85","series-title":"10th European College of Neuropsychopharmacology Congres; Sep 13-17; Vienna, Austria","article-title":"Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result","author":"Petrie","year":"1997"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006617.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0924-977X(06)70504-1","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic-induced hyperprolactinaemia","volume":"16","author":"Shim","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB87|cit87","series-title":"159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada","article-title":"Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients","author":"Swanson","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB88|cit88","first-page":"64","article-title":"Effect of aripiprazole or haldol on intelligence and memory in the first-onset schizophrenia","volume":"12","author":"Wu","year":"2006","journal-title":"Chinese Journal of Rehabilitation Theory and Practice"},{"issue":"10","key":"10.1002\/14651858.CD006617.pub2-BIB89|cit89","first-page":"33","article-title":"A treatment study of schizophrenia with aripiprazole and chlorpromazine","volume":"6","author":"Xia","year":"2005","journal-title":"Practical Clinical Medicine"},{"key":"10.1002\/14651858.CD006617.pub2-BIB90|cit90","series-title":"159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada","article-title":"Intramuscular (im) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation","author":"Currier","year":"2006"},{"key":"10.1002\/14651858.CD006617.pub2-BIB91|cit91","series-title":"159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada","article-title":"Transitioning from intramuscular (im) to oral aripiprazole in patients with schizophrenia","author":"Daniel","year":"2006"},{"key":"10.1002\/14651858.CD006617.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006617.pub2-BIB93|cit93","first-page":"1","article-title":"Negative syndrome in schizophrenia: strategies for long-term management","volume":"40","author":"Andreasen","year":"1985","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub2-BIB95|cit95","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006617.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006617.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/schbul\/17.2.217","article-title":"When symptoms persist: choosing among alternative somatic symptoms for schizophrenia","volume":"17","author":"Christison","year":"1991","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub2-BIB99|cit99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1192\/S0007125000071919","article-title":"Positive and negative schizophrenic symptoms and the role of dopamine","volume":"137","author":"Crow","year":"1980","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2165\/00003495-197714040-00002","article-title":"Antipsychotic drugs: clinical pharmacology and therapeutic use","volume":"14","author":"Davis","year":"1977","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006617.pub2-BIB101|cit101","series-title":"In: Abstracts of 8th InternationalCochrane Colloquim; 2000 Oct 25-28th; Cape Town, South Africa","article-title":"Issues in the selection for meta-analysis of binary data","author":"Deeks","year":"2000"},{"key":"10.1002\/14651858.CD006617.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behaviour","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006617.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomised trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub2-BIB104|cit104","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004578.pub3","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006617.pub2-BIB105|cit105","unstructured":"U.S. Federal Drug Administration CDER Abilify (aripiprazole) tablets, medical review www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002"},{"key":"10.1002\/14651858.CD006617.pub2-BIB106|cit106","first-page":"1314","article-title":"Antipsychotic and anticholinergic drugs","volume-title":"New Oxford Textbook of Psychiatry","volume":"2","author":"Gelder","year":"2000"},{"key":"10.1002\/14651858.CD006617.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006617.pub2-BIB108|cit108","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006617.pub2-BIB109|cit109","first-page":"48","article-title":"The Brief Psychiatric Rating Scale (BPRS): a comprehensive review","volume":"11","author":"Hedlund","year":"1980","journal-title":"Journal of Operational Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB110|cit110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006617.pub2-BIB111|cit111","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] Cochrane Database of Systematic Reviews 2005"},{"key":"10.1002\/14651858.CD006617.pub2-BIB112|cit112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled clinical trials"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB113|cit113","article-title":"Haloperidol versus placebo for schizophrenia","author":"Joy","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006617.pub2-BIB114|cit114","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"suppl","key":"10.1002\/14651858.CD006617.pub2-BIB115|cit115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0447.1990.tb05309.x","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"358","author":"Kane","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006617.pub2-BIB116|cit116","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006617.pub2-BIB117|cit117","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006617.pub2-BIB118|cit118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB119|cit119","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub2-BIB120|cit120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub2-BIB121|cit121","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","year":"1992","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub2-BIB122|cit122","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006617.pub2-BIB123|cit123","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub2-BIB124|cit124","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1037\/0735-7028.34.1.108","article-title":"Aripiprazole: A novel antipsychotic with dopamine stabilising properties","volume":"34","author":"Rivas-Vasquez","year":"2003","journal-title":"Professional Psychology: Research and Practice"},{"issue":"7127","key":"10.1002\/14651858.CD006617.pub2-BIB125|cit125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.316.7127.285","article-title":"What are pragmatic trials?","volume":"316","author":"Roland","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006617.pub2-BIB126|cit126","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD006617.pub2-BIB127|cit127","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006617.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T00:00:00Z","timestamp":1216166400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006617.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:01:51Z","timestamp":1628546511000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006617.pub2"}},"subtitle":[],"editor":[{"given":"Jayanti","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":127,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006617.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006617.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2008,1,23]]}}}